THERAPY DOSSIER · th-d9e308a959e8

Bacillus velezensis A2 LB fermentation broth

Other · Bacillus velezensis A2 LB fermentation broth; probiotic/microbial preparation.

Evidence & regulatory context

Mechanism: Bacillus velezensis A2 LB fermentation broth; probiotic/microbial preparation.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05606159 ↗NAwithdrawn

Tolerability and Effect of Bacillus velezensis DSM 33864 on Recurrent Clostridioides difficile Infection

Clostridium Difficile Infection Recurrence

Enrolment: 0 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30206282 ↗2018Reported benefit

Bacillus velezensis A2 fermentation exerts a protective effect on renal injury induced by Zearalenone in mice.

MouseChemical/toxinKunmingFemalen = Four groups of 10 mice per group (40 total)Oral gavage, without anaesthesia0.2 mL of A2 LB fermentation broth per animal per day, co-a…Co-administered with zearalenone in the same daily gavage

Model: Zearalenone-induced renal injury by daily oral gavage of 40 mg/kg zearalenone for 28 days

Co-administration of A2 fermentation broth reduced zearalenone-induced glomerular lobulation and atrophy, restored kidney index, lowered serum blood urea nitrogen, uric acid and creatinine (P < 0.01), inhibited the rise in malondialdehyde, restored total superoxide dismutase and glutathione peroxid…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…